Overview

Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer

Status:
Unknown status
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate survival in inoperable stage III Non-small Cell Lung Cancer patients following chemo-radiotherapy followed by GV1001 vaccination plus best supportive care.
Phase:
Phase 3
Details
Lead Sponsor:
Kael-GemVax Co., Ltd.
Collaborator:
Quintiles, Inc.